News | Proton Therapy | July 18, 2017

IBA to Install Proton Therapy Facility at Inova Schar Cancer Institute

Contract signed with Virginia facility for two-room Proteus Plus proton therapy system

IBA to Install Proton Therapy Facility at Inova Schar Cancer Institute

July 18, 2017 — IBA (Ion Beam Applications S.A.) and Inova recently signed a contract for a two-room Proteus Plus proton therapy solution, each treatment room equipped with pencil beam scanning capability and integrated cone beam computed tomography (CBCT). Inova plans to start treating patients by 2020 at the Inova Schar Cancer Institute on the Inova Center for Personalized Health campus in Annandale, Va.

“The addition of proton therapy to our oncology services will bring our patients access to one of the most significant technology innovations in the treatment of cancer,” said Thomas Graves, vice president for cancer services and associate director for administration at the Inova Schar Cancer Institute. “The Institute will be housed at the Inova Center for Personalized Health, offering patients easy access from anywhere in Virginia and the Metro DC area. This advanced technology will be an excellent complement to the best in class oncology services we offer today.”

Gopal Bajaj, M.D., chairman and medical director of radiation oncology at the Inova Schar Cancer Institute, added: “Being able to provide such a powerful cancer treatment truly puts Inova’s radiation oncology department at the forefront of cancer treatment delivery. Proton therapy is an exciting alternative to traditional radiation treatment protocols, allowing us to treat many cancer patients more effectively, and often without the uncomfortable side effects that traditional treatments may cause. This technology will have a very positive impact on the thousands of people in our community who are touched by cancer.”

For more information: www.iba-worldwide.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...